ClinicalTrials.gg
CompletedNCT03004040Updated Oct 5, 2026

Protection From Influenza: Determining the Impact of Prior Infection

An observational study in Influenza, sponsored by Health Sciences North Research Institute. Completed at 1 site in Canada. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Health Sciences North Research Institute · Observational

How we know

Updated Oct 5, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
45
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 157 studies in Influenza, Human with a site in Canada — 7 open to participants now, 12 under way, 4 of them phase 3. Influenza, Human · Canada.

Enrollment
24th of 26
45 · median 241
Started
2016
with 8 others
Observational
26 of 157
1 open now
Registered
123rd of 157
by date

Among the 157 studies in Influenza, Human with a site in Canada, this one is the 24th largest by enrollment of the 26 observational ones that give a count, is one of 9 that started in 2016, is one of 26 observational ones, and was the 123rd registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

7 of the 157 studies in Influenza, Human with a site in Canada are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 157 studies in Influenza, Human with a site in Canada, or all of them as a file.
02

Study summary

The investigators propose a unique methodology of studying infection and vaccination history and immune responses. As most studies in infection history are conducted on mice, limitations are inherent on their applicability to humans. A longitudinal comparison study following older adults (over the age of 65) hospitalized for influenza are followed through to their hospital discharge and vaccination in the following season. This will allow for the investigation of the course of infection, as well as impact on the response to vaccination.

Read the detailed description

Significance: This study will provide critical information on the best technique in vaccine candidate testing and improve influenza treatment approaches. The long-term goal of this research is to identify the T-cell responses that are surrogates (biomarkers) of serious complications of influenza in older adults and predict vaccine efficacy (prevention of influenza illness) and vaccine effectiveness (prevention of serious complications). Further, translating new insights into age-related immune dysfunction to the design of new influenza vaccines is critical to addressing this unmet need in the population aged 65 and older.

Innovation: The study will help in the validation of clinical tools and biomarkers as prognostic indicators of influenza illness severity in vaccinated older adults, point-of-care diagnostics that would direct other preventive strategies to reduce the impact of influenza illness in vaccinated older adults, and correlates of protection to evaluate the potential of new influenza vaccines to enhance protection against the serious complications of influenza illness. The investigators have established that GrzB activity and the IFNg: IL-10 ratio in influenza-stimulated PBMC correlate with protection against influenza, and preliminary data to show that low GrzB activity in influenza-stimulated PBMC correlates with more severe disease and higher levels of frailty. The innovations of this project are the established methods for developing correlates of protection, the clinical insights into how frailty affects immune-mediated protection against influenza, and the direct translation of this research to provide a reasonable method for primary care clinicians to estimate vaccine effectiveness in an individual older person. These results will translate to the practical design of clinical trials to evaluate the potential for new influenza vaccines to better protect against the serious complications of influenza and complement those based on antibody titers and/or clinical outcomes alone.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Older adult patients (over the age of 65) admitted to Health Sciences North with laboratory confirmed influenza illness (LCII) and matched control subjects (non-LCII).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written provided by the participant.
  2. Age 65 years of age or older admitted to Health Sciences North with at least one the following:

    • Laboratory confirmed influenza illness
    • Acute exacerbation of (AECOPD).
    • Any respiratory or influenza-like symptoms (dyspnea, cough, sore throat, myalgia, arthralgia, fever, delirium/altered level of consciousness) that a test for influenza was negative.
  3. Willing to receive influenza vaccination in the subsequent flu season

Exclusion criteria

Exclusion Criteria:

  1. Patients whose reason for hospital admission was unrelated to influenza or (for example patients admitted due to trauma, elective surgery, or patients who have an alternative diagnosis that is clearly not respiratory).
  2. Chest x-ray positive for pneumonia.
  3. Study participants who cannot be vaccinated due to previous severe reaction to influenza vaccine, egg, latex, or thimerosol allergies, or refusal of vaccination.
  4. disorders or medications (including oral prednisone in doses >10 mg daily).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
45 participants (actual)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Case

    older adult patients (over the age of 65) admitted to Health Sciences North with laboratory confirmed influenza illness (LCII)

    Biological: Flu Vaccine

  • Control

    matched control subjects (non-LCII)

    Biological: Flu Vaccine

Interventions

  • BiologicalFlu Vaccine
06

What researchers measure

Primary outcomes

  1. High expression of CTL associated cytokines and granzymes in PBMC's are predictors of influenza infection severity.

    PBMCs from adults hospitalized for laboratory confirmed influenza illness (LCII) will be collected at admission and 30 days post hospitalization. These samples will be matched with hospitalized non-LCII adult controls. T-cells will be isolated from whole blood samples and gene expression of IFNg, IL10 and GrzB will be measured and compared between time points and subjects. These levels do not have a separate unit of measure.

    Time frame: 2 years

Secondary outcomes

  1. Vaccination in previously infected individuals increases the protection provided by subsequent vaccination and will be higher than those receiving vaccination alone (with no previous infection)

    Older adults hospitalized for influenza illness the previous season will be compared to matched, hospitalized older adults with influenza-like illness (non-LCII). PBMCs will be collected from each group, before receiving influenza vaccination and 4 weeks after vaccination. PBMCs will be challenged ex vivo with influenza virus and gene expression of CTL related genes will be measured and compared between each group.

    Time frame: 2 years

07

Study locations

1 site
  • Health Sciences North Research Institute
    Greater Sudbury, Ontario P3E 5J1, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Dec 2016, a primary completion of Apr 2020 and a completion of Apr 2020. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Jan 2019 → Apr 2020 and completion Jan 2019 → Apr 2020.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2016
First posted
Dec 28, 2016
Start
Dec 2016
Primary completionActual
Apr 1, 2020was Jan 2019
CompletionActual
Apr 1, 2020was Jan 2019
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 5, 2026
Sites
1 site added, 1 site removed
Show site
  • Health Sciences North Research Institute · Greater Sudbury, Canada
Show 1 removed
  • Health Sciences North Research Institute · Sudbury, Canada
Oct 5, 2026
Primary completion
Jan 2019→Apr 1, 2020 (actual)
Oct 5, 2026
Study completion
Jan 2019→Apr 1, 2020 (actual)
Oct 5, 2026
Enrollment
50 (estimated)→45 (actual)
Oct 5, 2026
Sponsor
Collaborators added: NORTHERN ONTARIO ACADEMIC MEDICINE ASSOCIATION (NOAMA); collaborators removed: NOAMA NORTHERN ONTARIO ACADEMIC MEDICINE ASSOCIATION
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Status unknown→Completed
    1 site added, 1 site removed
    Show site
    • Health Sciences North Research Institute · Greater Sudbury, Canada
    Show 1 removed
    • Health Sciences North Research Institute · Sudbury, Canada
    Primary completion Jan 2019→Apr 1, 2020 (now actual)
    Study completion Jan 2019→Apr 1, 2020 (now actual)
    Enrollment 50 (estimated)→45 (actual)
    Sponsor Collaborators added: NORTHERN ONTARIO ACADEMIC MEDICINE ASSOCIATION (NOAMA); collaborators removed: NOAMA NORTHERN ONTARIO ACADEMIC MEDICINE ASSOCIATION
    + 4 other changes: identifiers, verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03004040
Lead sponsor
Health Sciences North Research Institute
Collaborators
NORTHERN ONTARIO ACADEMIC MEDICINE ASSOCIATION (NOAMA)
Responsible party
Sponsor
First posted
Dec 28, 2016
Start date
Dec 2016
Primary completion
Apr 1, 2020
Completion
Apr 1, 2020
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion